Issue Date: November 14, 2011
Mylan Will Acquire Pfizer Technology
Mylan will acquire the rights to develop Pfizer’s generic equivalent to GlaxoSmithKline’s Advair Diskus and Seretide Diskus inhaler-based asthma drugs. Mylan will pay Pfizer $17.5 million plus additional payments contingent on regulatory and commercial success. In connection with the deal, Mylan will hire select employees from the former Pfizer respiratory inhalation development team based in Sandwich, England, where Mylan will set up a respiratory development division. Mylan says the deal expands its focus on difficult-to-produce, limited-competition products.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society